The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCOS.L Regulatory News (COS)

  • There is currently no data for COS

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director/PDMR Shareholding

28 Aug 2020 15:27

RNS Number : 5084X
Collagen Solutions PLC
28 August 2020
 

Collagen Solutions plc

(the "Company")

 

Director/PDMR Dealing

 

1. Vesting / exercise of Deferred Bonus Awards granted in October 2019

 

Collagen Solutions plc (AIM: COS), the developer and manufacturer of biomaterials and regenerative medicines for the enhancement and extension of human life, announces that, on 28 August 2020, the executive director and other persons discharging managerial responsibility ("PDMRs") set out in the table below acquired ordinary shares of 1 pence each in the share capital of the Company ("Shares") pursuant to the vesting / exercise of awards originally granted under the Collagen Solutions plc Deferred Bonus Plan on 2 October 2019 (the "Awards"). No consideration was payable for these Shares.

 

Director/PDMR

Position

Number of Shares acquired on 28 August 2020

Jamal Rushdy

Chief Executive Officer

906,145

Lou Ruggiero

Chief Business Officer

806,559

Brad Selman

PDMR / VP Global Sales and Marketing

284,202

Chris Wattengel

PDMR / VP Global R&D

246,514

Kevin Darling

PDMR / VP Tissue Products

173,596

 

Notes:

1 A number of other individuals, including Hilary Spence, Chief Financial Officer, were also granted Awards under the Deferred Bonus Plan on 2 October 2019. Although these Awards (which are in the form of "nil-cost" options) have now vested, the relevant holders have not yet elected to exercise their rights and acquire their Shares.

 

The Shares required to satisfy the above vestings / exercises were transferred to the relevant individuals by the trustee of the Collagen Solutions plc Employee Benefit Trust (the "EBT"). As previously announced, these Shares were allotted to the EBT on 11 August 2020.

 

2. Total beneficial holdings in the Company

 

Following the above notifications, the total holdings of Shares of the relevant PDMRs are as follows:

 

Director/PDMR

Position

Total holding following this notification

Approximate % of the Company's issued share capital

Jamal Rushdy

Chief Executive Officer

1,906,145

0.43%

Lou Ruggiero

Chief Business Officer

806,559

0.18%

Brad Selman

PDMR / VP Global Sales and Marketing

284,202

0.06%

Chris Wattengel

PDMR / VP Global R&D

246,514

0.06%

Kevin Darling

PDMR / VP Tissue Products

173,596

0.04%

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

1. Jamal Rushdy

2. Lou Ruggiero

3. Brad Selman

4. Chris Wattengel

5. Kevin Darling

2

Reason for the notification

a)

Position/status

1. Chief Executive Officer

2. Chief Business Officer

3. PDMR / VP Global Sales and Marketing

4. PDMR / VP Global R&D

5. PDMR / VP Tissue Products

b)

Initial notification/ Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Collagen Solutions plc

b)

LEI

213800IFY1CVGRGETL95

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Ordinary shares of 1p each ("Shares")

Identification code

ISIN Code: GB00B94T6Y14

b)

Nature of the transaction

Acquisition of Shares on the vesting / exercise of Awards originally granted on 2 October 2019 pursuant to the Collagen Solutions plc Deferred Bonus Plan

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

1.

nil

906,145

2.

nil

806,559

3.

nil

284,202

4.

nil

246,514

5.

nil

173,596

d)

Aggregated information

- Aggregated volume

- Price

1. N/A single transaction

2. N/A single transaction

3. N/A single transaction

4. N/A single transaction

5. N/A single transaction

e)

Date of the transaction

2020-08-28

f)

Place of the transaction

Outside a trading venue

 

Enquiries:

Collagen Solutions Plc

Jamal Rushdy, CEO

 

Hilary Spence, CFO

Via Walbrook

Cenkos Securities Plc (Nominated Adviser and Broker)

Giles Balleny (Corporate Finance)

Tel: 0207 397 8900

Stephen Keys

Walbrook PR Ltd

Tel: 020 7933 8780 or collagen@walbrookpr.com

Anna Dunphy

Mob: 07876 741 001

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHKKFBBQBKDPFB
Date   Source Headline
30th Aug 201711:21 amRNSResult of AGM
30th Aug 20177:00 amRNSAGM Statement
26th Jul 20177:00 amRNSPosting of Annual Report & notice of AGM
25th Jul 201711:36 amRNSDirector/PDMR Shareholding
25th Jul 20177:15 amRNSHardman Research: Transition to sustainable growth
13th Jul 201711:39 amRNSDirector/PDMR Shareholding
11th Jul 20177:00 amRNSFinal Results
7th Jul 20177:00 amRNSFirst patient enrolment in ChondroMimetic® study
19th Jun 20177:00 amRNSNotice of Results
13th Jun 20177:00 amRNSProvisional patent submitted
11th May 20177:15 amRNSHardman Research: Trading:earnings above forecasts
25th Apr 20177:00 amRNSTrading Update
24th Apr 20177:00 amRNSConsolidation of US R&D activities & Board change
10th Apr 20177:00 amRNSCollagen Based Spray Adhesive Poster Presented
3rd Apr 201711:22 amRNSHolding(s) in Company
3rd Apr 20177:00 amRNSAgreement signed with Smart Matrix Limited
31st Mar 20174:52 pmRNSHolding(s) in Company
29th Mar 20177:00 amRNSPericardium Divisional Patent in Australia
27th Mar 201712:39 pmRNSDirector/PDMR Shareholding
24th Mar 20179:26 amRNSDirector/PDMR Shareholding
23rd Mar 20177:00 amRNSAttending UK Investor Show
20th Mar 20178:56 amRNSIntroduces new online sales initiative in the US
15th Mar 20179:58 amRNSHolding(s) in Company
14th Mar 20173:28 pmRNSHolding(s) in Company
13th Mar 201711:52 amRNSHardman Research: Engineering cartilage repairs
13th Mar 20179:57 amRNSHolding(s) in Company
13th Mar 20177:05 amRNSHardman Research: Engineering cartilage repairs
9th Mar 20177:00 amRNSHolding(s) in Company
9th Mar 20177:00 amRNSAttending AAOS and ORS meetings in San Diego
9th Mar 20177:00 amRNSHolding(s) in Company
8th Mar 20177:00 amRNSDirector/PDMR Shareholding
7th Mar 20174:08 pmRNSHolding(s) in Company
7th Mar 20171:01 pmRNSDirector/PDMR Shareholding
7th Mar 201711:19 amRNSHolding(s) in Company
7th Mar 20179:56 amRNSHolding(s) in Company
6th Mar 20172:24 pmRNSResult of General Meeting
20th Feb 20177:00 amRNSInvestor presentation
15th Feb 201711:29 amRNSGrant of Options
14th Feb 201711:24 amRNSHardman Research: Funding accelerated growth
14th Feb 20177:00 amRNSPlacing Open Offer and Debt Financing
7th Feb 20177:00 amRNSAttends MD&M West Conference in Anaheim
19th Jan 20177:00 amRNSNew Scientific Advisory Board appointments
13th Jan 20177:00 amRNSThird Medical Research Scotland Ph.D. Studentship
21st Dec 201612:06 pmRNSHardman Research: Foundations for strategic growth
19th Dec 20167:00 amRNSHalf-year Report
14th Dec 20167:00 amRNSPoster Presentation at TERMIS-AM
2nd Dec 20167:00 amRNSNotice of Results
13th Oct 20167:00 amRNSTrading Statement
3rd Oct 20167:00 amRNSChange of Adviser
15th Sep 20167:00 amRNSParticipation in major Horizon 2020 project

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.